Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations

被引：25

作者：

Maes, Helena ^{[1
]}

Delforge, Michel ^{[1
]}

机构：

[1] Univ Leuven, Dept Hematol, Herestr 49, B-3000 Louvain, Belgium

来源：

EXPERT REVIEW OF HEMATOLOGY | 2015年 / 8卷 / 03期

关键词：

elderly; geriatric assessment; multiple myeloma; quality of life; tailored therapy; TRANSPLANT-INELIGIBLE PATIENTS; HIGH-DOSE DEXAMETHASONE; ELDERLY-PATIENTS; GERIATRIC ASSESSMENT; ADVERSE EVENTS; OLDER PATIENTS; PHASE-III; BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE;

D O I：

10.1586/17474086.2015.1021772

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Multiple myeloma (MM) is a plasma cell neoplasm with a chronic disease course that primarily affects elderly individuals. The introduction of novel agents such as thalidomide, lenalidomide and bortezomib has significantly improved the outcome for MM patients, including the elderly. Quality of life in MM is influenced by disease-related symptoms, treatment-related toxicity and treatment response. In addition to conventional endpoints as response, quality of life should be carefully evaluated during each therapeutic phase. Caring for older adults with MM is particularly challenging because of the heterogeneity of aging and the presence of comorbidities and frailty, with a potential risk of over- or under-treatment. Moreover, elderly patients may sometimes prioritize maintaining quality of life above prolonging survival. A careful evaluation of comorbidities and a geriatric assessment can facilitate risk-stratification of elderly patients to identify the older population fit enough to tolerate standard drug dosing, and to detect the frail patients who need age-adapted treatment.

引用

页码：355 / 366

页数：12

共 59 条

[11] Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial [J].

Delforge, Michel ;

Dhawan, Ravinder ;

Robinson, Don, Jr. ;

Meunier, Juliette ;

Regnault, Antoine ;

Esseltine, Dixie-Lee ;

Cakana, Andrew ;

van de Velde, Helgi ;

Richardson, Paul G. ;

San Miguel, Jesus F. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 89 (01) :16-27

[12] Impact of Complete Response on Quality of Life in Newly Diagnosed Multiple Myeloma Patients [J].

Dhawan, R. ;

Meunier, J. ;

Regnault, A. ;

Robinson, D., Jr. ;

Rosa, K. ;

Cakana, A. ;

de Velde, H. V. ;

Richardson, P. G. ;

Miguel, J. San .

CLINICAL LYMPHOMA & MYELOMA, 2009, 9 :S58-S58

[13] Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial [J].

Dimopoulos, Meletios A. ;

Delforge, Michel ;

Hajek, Roman ;

Kropff, Martin ;

Petrucci, Maria T. ;

Lewis, Philip ;

Nixon, Annabel ;

Zhang, Jingshan ;

Mei, Jay ;

Palumbo, Antonio .

HAEMATOLOGICA, 2013, 98 (05) :784-788

[14] Descriptive and prognostic value of patient-reported outcomes: The bortezomib experience in relapsed and refractory multiple myeloma [J].

Dubois, D ;

Dhawan, R ;

van de Velde, H ;

Esseltine, D ;

Gupta, S ;

Viala, M ;

de la Loge, C .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :976-982

[15]

Espinoza-Zamora J, 2015, ANN HEMATOL

[16]

Fried LP, 2004, J GERONTOL A-BIOL, V59, P255

[17] The relevance of a geriatric assessment for elderly patients with a haematological malignancy - A systematic review [J].

Hamaker, M. E. ;

Prins, M. C. ;

Stauder, R. .

LEUKEMIA RESEARCH, 2014, 38 (03) :275-283

[18] Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study [J].

Hjorth, Martin ;

Hjertner, Oyvind ;

Knudsen, Lene Meldgaard ;

Gulbrandsen, Nina ;

Holmberg, Erik ;

Pedersen, Per Trollund ;

Andersen, Niels Frost ;

Andreasson, Bjorn ;

Billstrom, Rolf ;

Carlson, Kristina ;

Carlsson, Margaretha S. ;

Flogegard, Max ;

Forsberg, Karin ;

Gimsing, Peter ;

Karlsson, Torbjorn ;

Linder, Olle ;

Nahi, Hareth ;

Othzen, Annika ;

Swedin, Agneta .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 88 (06) :485-496

[19] Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study [J].

Jordan, Karin ;

Proskorovsky, Irina ;

Lewis, Philip ;

Ishak, Jack ;

Payne, Krista ;

Lordan, Noreen ;

Kyriakou, Charalampia ;

Williams, Cathy D. ;

Peters, Sarah ;

Davies, Faith E. .

SUPPORTIVE CARE IN CANCER, 2014, 22 (02) :417-426

[20] Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study [J].

Kenis, C. ;

Bron, D. ;

Libert, Y. ;

Decoster, L. ;

Van Puyvelde, K. ;

Scalliet, P. ;

Cornette, P. ;

Pepersack, T. ;

Luce, S. ;

Langenaeken, C. ;

Rasschaert, M. ;

Allepaerts, S. ;

Van Rijswijk, R. ;

Milisen, K. ;

Flamaing, J. ;

Lobelle, J-P ;

Wildiers, H. .

ANNALS OF ONCOLOGY, 2013, 24 (05) :1306-1312

← 1 2 3 4 5 6 →